Gland Pharma Q1FY26 Revenue ₹15,056 Mn, PAT up by 50% YoY
The significant increase in PAT and EBITDA margin, along with the achievement of EBITDA breakeven for Cenexi and new product launches, indicates a positive impact on the company's financial health and future prospects.
The announcement highlights strong financial performance, including increased revenue, profit, and EBITDA margin, as well as positive developments such as new product launches and regulatory approvals.
* Gland Pharma reported revenue of ₹15,056 million for Q1FY26, a 7% increase year-on-year. * Profit After Tax (PAT) increased by 50% year-on-year to ₹2,155 million. * EBITDA margin increased by 549 bps year-on-year to 24%. * Cenexi achieved EBITDA breakeven for the quarter. * The company launched 12 new molecules in regulated markets. * One ANDA was filed and nine were approved in Q1 FY26, with a cumulative total of 372 ANDA filings in the U.S. (325 approved, 47 pending). * Total R&D expenses were ₹460 million in Q1 FY26, representing 4.4% of revenue. * Gland Pharma is increasing its GLP-1/Pen/cartridge capacity from approximately 40 million to 140 million units.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.